logo
Plus   Neg
Share
Email

Innogy Q1 Adj. EBIT Down; Confirms 2019 Outlook - Quick Facts

Innogy SE (IGY.DE), a German energy utility, reported that its adjusted EBIT for the first quarter of 2019 was 964 million euros, substantially down year on year. Adjusted net income fell to 407 million euros. This was primarily due to developments in the UK retail business and the sale of the Czech gas grid business

For fiscal 2019 as a whole, innogy expects net investment to be considerably higher than in the previous year. This does not include the proceeds from the sale of its Czech gas grid business.

innogy confirmed its outlook for 2019 at both Group and divisional levels. It expects adjusted EBIT of about 2.3 billion euros for the current fiscal year, which represents a substantial decline year on year. The main reasons for this decline are the sale of the Czech gas grid business in February 2019, which will thus no longer contribute to the result for the balance of the year, the introduction of the Standard Variable Tariff price cap, and higher regulatory costs in the UK retail business.

Like the change in adjusted EBIT, the outlook for adjusted net income is also well below the figure for the previous year, at about 850 million euros.

For its dividend payment, innogy aims to continue paying out 70 to 80 per cent of its adjusted net income.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Deutsche Post DHL Group were gaining around 5 percent in the morning trading in Germany after the package delivery and supply chain management company reported Tuesday significantly higher profit in its third quarter. Looking ahead, the company anticipates a traditionally strong holiday season in the fourth quarter. The company also confirmed its annual earnings outlook. A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions.
Follow RTT
>